July 15, 2022
On Track for FY 2022 Guidance Q1 2022 revenue rises 3% to €10.3 million Completed phase out of COVID-19 Business segment in Q1 2022 Positioning Pharma and Diagnostics for post-COVID recovery and growth in 2022 and beyond Reaffirms FY 2022 guidance of 15-20% revenue growth CAMBRIDGE, Mass.
March 30, 2022
- Full Year 2021 Total Revenue Growth of 48%, and 11% in Core Business Segments, Exceeds Guidance - Focus on Pharma and Diagnostics to Position for Strong Performance in 2022 - Closed $62 Million Financing Round and on Track to Exit COVID-19 Business - Management to Host Conference Call at 2 p.m.
Displaying 1 - 10 of 19